![Lawrence Kenyon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lawrence Kenyon
Geen lopende functies
Vermogen: 67 703 $ op 31-08-2026
Profiel
Lawrence A. Kenyon served as Chief Financial Officer, Secretary & EVP at NeoPharm, Inc. from 2000 to 2006.
Served as Director at Tamir Biotechnology, Inc. in 2009.
Served as Chief Financial Officer at Par Pharmaceutical, Inc. from 2009 to 2010.
Served as Chief Financial Officer & Executive Vice President at Endo Generics Holdings, Inc. from 2009 to 2010.
Served as President, CEO, CFO & Secretary at Tamir Biotechnology, Inc. in 2013.
Served as Chief Operating & Financial Officer at Arno Therapeutics, Inc. from 2014 to 2015.
Served as CEO, CFO, Secretary, Treasurer & Director at Outlook Therapeutics, Inc. from 2024 to 2025.
Attended the University of Wisconsin, completing undergraduate studies in 1987.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 14-08-2026 | 106.956 ( 0,07% ) | 67 703 $ | 31-08-2026 |
Eerdere bekende functies van Lawrence Kenyon
| Bedrijven | Functie | Einde |
|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Algemeen Directeur | 01-07-2025 |
| ARNO THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-09-2015 |
Tamir Biotechnology, Inc.
 Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Algemeen Directeur | 31-03-2013 |
Par Pharmaceutical, Inc.
 Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets generic drugs and pharmaceuticals products | Financieel Directeur/CFO | 01-07-2010 |
| PAR PHARMACEUTICAL COMPANIES, INC. | Financieel Directeur/CFO | 04-06-2010 |
Opleiding van Lawrence Kenyon
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
89
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Health Technology |
Endo Generics Holdings, Inc.
 Endo Generics Holdings, Inc. Pharmaceuticals: GenericHealth Technology Operates as a holding company with interests in developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States | Health Technology |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology Provides drug research, development and commercialization services | Health Technology |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets generic drugs and pharmaceuticals products | Health Technology |
Arno Therapeutics, Inc.
 Arno Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs | Health Technology |
Outlook Therapeutics, Inc.
 Outlook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures bevacizumab therapeutic products | Health Technology |
